86703

Antibody; HIV-1 and HIV-2, single result

CPT code 86703 describes a qualitative laboratory procedure used to detect antibodies for both Human Immunodeficiency Virus type 1 (HIV-1) and Human Immunodeficiency Virus type 2 (HIV-2) in a patient's serum or plasma, yielding a single result. This test is typically performed using Enzyme Immunoassay (EIA) or Enzyme-Linked Immunosorbent Assay (ELISA) technology. HIV is the causative agent of Acquired Immunodeficiency Syndrome (AIDS). HIV-1 is the most common strain found worldwide, while HIV-2 is primarily localized to West Africa but has been identified globally. The detection of antibodies is a standard method for identifying individuals who have been infected with the virus, as the immune system typically produces these antibodies within three to twelve weeks following exposure. In the clinical setting, the 86703 assay is often utilized as a screening tool. Because the test produces a 'single result,' it indicates the presence or absence of antibodies to either virus without necessarily distinguishing which specific type is present. If the screening result is reactive (positive), current clinical protocols usually dictate follow-up with a confirmatory assay or a differentiation immunoassay to verify the infection and identify the specific virus type. It is distinct from newer 4th generation tests that detect both antibodies and the p24 antigen (CPT 87389). Providers must ensure that clinical documentation supports the medical necessity for HIV screening, whether based on high-risk behavior, pregnancy, or routine screening recommendations provided by organizations such as the USPSTF.

Clinical Indications

  • Routine screening for HIV-1 and HIV-2 in asymptomatic individuals aged 15 to 65.
  • Evaluation of patients with symptoms suggestive of acute retroviral syndrome (e.g., fever, lymphadenopathy, rash).
  • Prenatal screening for all pregnant individuals to prevent mother-to-child transmission.
  • Post-exposure prophylaxis (PEP) baseline testing after potential occupational or non-occupational exposure.
  • Pre-exposure prophylaxis (PrEP) baseline and periodic monitoring.
  • Evaluation of patients with sexually transmitted infections (STIs).
  • Screening for individuals with known high-risk behaviors, including multiple sexual partners or intravenous drug use.
  • Workup for patients presenting with opportunistic infections or AIDS-defining illnesses.

Procedure Steps

  1. Collect a venous blood sample from the patient using standard phlebotomy techniques into a collection tube (typically a serum separator or heparinized tube).
  2. Centrifuge the blood sample to separate the serum or plasma from the cellular components.
  3. Transfer the serum or plasma to the laboratory analyzer or prepared reaction wells containing HIV-1 and HIV-2 antigens.
  4. Incubate the specimen to allow any HIV antibodies present in the patient sample to bind with the immobilized antigens in the assay.
  5. Perform a wash cycle to remove any unbound proteins or non-specific antibodies from the reaction site.
  6. Add an enzyme-conjugated secondary antibody (conjugate) that binds to the human HIV antibodies, followed by another incubation period.
  7. Perform a second wash cycle to remove unbound conjugate.
  8. Add a substrate or chromogen that reacts with the enzyme to produce a measurable signal (color change or fluorescence).
  9. Measure the signal intensity using a spectrophotometer or automated reader and compare it against a predetermined cutoff value to determine a 'reactive' or 'non-reactive' result.
  10. Report the single qualitative result to the ordering provider.

Coding Guidelines

  • Report 86703 when a single assay is performed that detects antibodies for both HIV-1 and HIV-2 and provides a single integrated result.
  • If the laboratory performs separate assays for HIV-1 and HIV-2 and reports separate results, use codes 86701 and 86702 respectively.
  • Do not report 86703 in conjunction with 87389 (HIV-1/HIV-2 antigen/antibody) if the 4th generation combination test is used.
  • For confirmatory testing such as Western Blot or specific differentiation assays, use the appropriate specific CPT code (e.g., 86689).
  • If the test is performed as a CLIA-waived procedure (e.g., rapid oral or fingerstick), append modifier -QW if required by the payer.
  • For screening purposes, ensure the appropriate ICD-10 screening code (Z11.4) is used to indicate the encounter is for HIV screening in an asymptomatic patient.

Associated ICD-10 Codes